These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 33501446)

  • 1. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
    Wibmer CK; Ayres F; Hermanus T; Madzivhandila M; Kgagudi P; Oosthuysen B; Lambson BE; de Oliveira T; Vermeulen M; van der Berg K; Rossouw T; Boswell M; Ueckermann V; Meiring S; von Gottberg A; Cohen C; Morris L; Bhiman JN; Moore PL
    bioRxiv; 2021 Mar; ():. PubMed ID: 33501446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
    Wibmer CK; Ayres F; Hermanus T; Madzivhandila M; Kgagudi P; Oosthuysen B; Lambson BE; de Oliveira T; Vermeulen M; van der Berg K; Rossouw T; Boswell M; Ueckermann V; Meiring S; von Gottberg A; Cohen C; Morris L; Bhiman JN; Moore PL
    Nat Med; 2021 Apr; 27(4):622-625. PubMed ID: 33654292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
    Cele S; Gazy I; Jackson L; Hwa SH; Tegally H; Lustig G; Giandhari J; Pillay S; Wilkinson E; Naidoo Y; Karim F; Ganga Y; Khan K; Bernstein M; Balazs AB; Gosnell BI; Hanekom W; Moosa MS; ; ; Lessells RJ; de Oliveira T; Sigal A
    Nature; 2021 May; 593(7857):142-146. PubMed ID: 33780970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.
    Li Q; Nie J; Wu J; Zhang L; Ding R; Wang H; Zhang Y; Li T; Liu S; Zhang M; Zhao C; Liu H; Nie L; Qin H; Wang M; Lu Q; Li X; Liu J; Liang H; Shi Y; Shen Y; Xie L; Zhang L; Qu X; Xu W; Huang W; Wang Y
    Cell; 2021 Apr; 184(9):2362-2371.e9. PubMed ID: 33735608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2.
    Saade C; Gonzalez C; Bal A; Valette M; Saker K; Lina B; Josset L; Trabaud MA; Thiery G; Botelho-Nevers E; Paul S; Verhoeven P; Bourlet T; Pillet S; Morfin F; Trouillet-Assant S; Pozzetto B; On Behalf Of Covid-Ser Study Group
    Emerg Microbes Infect; 2021 Dec; 10(1):1499-1502. PubMed ID: 34176436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. South African (501Y.V2) and the United Kingdom (B.1.1.7) SARS-CoV-2 Spike (S) Protein Variants Demonstrate a Higher Binding Affinity to ACE2.
    Mohammad A; Abubaker J; Al-Mulla F
    Comb Chem High Throughput Screen; 2023; 26(3):589-594. PubMed ID: 35674297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.
    Moyo-Gwete T; Madzivhandila M; Makhado Z; Ayres F; Mhlanga D; Oosthuysen B; Lambson BE; Kgagudi P; Tegally H; Iranzadeh A; Doolabh D; Tyers L; Chinhoyi LR; Mennen M; Skelem S; Marais G; Wibmer CK; Bhiman JN; Ueckermann V; Rossouw T; Boswell M; de Oliveira T; Williamson C; Burgers WA; Ntusi N; Morris L; Moore PL
    bioRxiv; 2021 Mar; ():. PubMed ID: 33688657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.
    Villoutreix BO; Calvez V; Marcelin AG; Khatib AM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 501Y.V2 spike protein resists the neutralizing antibody in atomistic simulations.
    Ngo ST
    Comput Biol Chem; 2022 Apr; 97():107636. PubMed ID: 35066438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.
    Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitive Immunodetection of Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern 501Y.V2 and 501Y.V1.
    Barlev-Gross M; Weiss S; Paran N; Yahalom-Ronen Y; Israeli O; Nemet I; Kliker L; Zuckerman N; Glinert I; Noy-Porat T; Alcalay R; Rosenfeld R; Levy H; Mazor O; Mandelboim M; Mendelson E; Beth-Din A; Israely T; Mechaly A
    J Infect Dis; 2021 Aug; 224(4):616-619. PubMed ID: 34398244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
    Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
    bioRxiv; 2021 Aug; ():. PubMed ID: 34462749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets.
    Riddell S; Goldie S; McAuley AJ; Kuiper MJ; Durr PA; Blasdell KR; Tachedjian M; Druce JD; Smith TRF; Broderick KE; Vasan SS
    Front Immunol; 2021; 12():694857. PubMed ID: 34248993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.
    Cao Y; Yisimayi A; Bai Y; Huang W; Li X; Zhang Z; Yuan T; An R; Wang J; Xiao T; Du S; Ma W; Song L; Li Y; Li X; Song W; Wu J; Liu S; Li X; Zhang Y; Su B; Guo X; Wei Y; Gao C; Zhang N; Zhang Y; Dou Y; Xu X; Shi R; Lu B; Jin R; Ma Y; Qin C; Wang Y; Feng Y; Xiao J; Xie XS
    Cell Res; 2021 Jul; 31(7):732-741. PubMed ID: 34021265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab
    Liu H; Wei P; Zhang Q; Chen Z; Aviszus K; Downing W; Peterson S; Reynoso L; Downey GP; Frankel SK; Kappler J; Marrack P; Zhang G
    MAbs; 2021; 13(1):1919285. PubMed ID: 34074219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
    Jia Z; Gong W
    J Korean Med Sci; 2021 May; 36(18):e124. PubMed ID: 33975397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.
    Singh J; Samal J; Kumar V; Sharma J; Agrawal U; Ehtesham NZ; Sundar D; Rahman SA; Hira S; Hasnain SE
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33803400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid screening for SARS-CoV-2 variants of concern in clinical and environmental samples using nested RT-PCR assays targeting key mutations of the spike protein.
    La Rosa G; Mancini P; Bonanno Ferraro G; Veneri C; Iaconelli M; Lucentini L; Bonadonna L; Brusaferro S; Brandtner D; Fasanella A; Pace L; Parisi A; Galante D; Suffredini E
    Water Res; 2021 Jun; 197():117104. PubMed ID: 33857895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.